Calithera Biosciences appoints Suzy Jones to the Board of Directors and its Audit Committee

– USA, CA – Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of Suzy Jones to the company’s Board of Directors, where she will be a member of the company’s Audit Committee. Ms. Jones is currently Founder and Managing Partner of DNA Ink, a boutique life sciences advisory firm.

“The addition of such a seasoned biotechnology executive will add another key life science expert to our board,” said Susan Molineaux, PhD, President and Chief Executive Officer. “As we advance our tumor metabolism and tumor immunology therapeutics through clinical development, we believe Suzy will make important strategic contributions that will help us develop our pipeline with an eye toward potential product commercialization.”

Prior to founding DNA Ink, Suzy spent 20 years at Genentech in various roles in immunology research, product development managing cross functional teams for RITUXAN and AVASTIN, and business development where she was Head of Non-Oncology Licensing and later Interim Head of Partnering and Head of Business Development. Suzy’s group helped to diversify Genentech’s portfolio through licensing. During her time in business development, the group was recognized in an independent IBM survey as the number one deal making and sourcing group in the world. In 2010, she was named by Black Health Magazine as one of the, “Top 25 Most Influential African Americans in Healthcare, Medicine, Pharmaceutical and Food Industries.” Suzy serves as a member of the board of directors of Patrys, an ASX listed Australian biotechnology company. She received a degree in Biology from University of California, Santa Cruz.

About Calithera

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in Phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, an immunosuppressive enzyme in myeloid-derived suppressor cells responsible for T-cell suppression. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. Calithera is headquartered in South San Francisco, California.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>